Silvadene

(Silver Sulfadiazine)

PreclinicalSmall molecule

RRosalind Franklin University of Medicine and Science

Silvadene is one of 41 small molecule programs targeting Breast Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Breast CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Lexiscan

Astellas

Preclinical

1 2

Voltaren

Novartis

Preclinical

1 3

Zolymbus

AbbVie

Preclinical

1 4

Blenoxane

Bristol-Myers Squibb

Preclinical

1 5

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 7

Duragesic-100

CCephalon

Preclinical

2 8

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 9

Spravato

WWim Janssens

Preclinical

2 10

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ANot yet recruiting

Hyaluronic Acid

NCT07367087

Clinical

Trials by Indication[1]

Burns1 trial

Comparison of a Water-soluble Topical Antimicrobial to Silver Sulfadiazine in Partial Thickness Burns

Completed·UUniversity of Virginia·Phase 4·NCT01926392·8 enrolled

Effectiveness1 trial

Comparative Analysis of Cost-effectiveness of Silver Dressing in Burns

Completed·UUniversity of Sorocaba·Phase 4·NCT02108535·100 enrolled

Burn1 trial

Superficial Partial-Thickness Burn Study

Terminated·—·Phase 4·NCT04601532·26 enrolled

Breast Cancer1 trial

StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or Head and Neck Cancer Patients

Withdrawn·OOHSU Knight Cancer Institute·N/A·NCT05073172

Hyaluronic Acid1 trial

Silver Sulfadiazine With Hyaluronic Acid Versus Silver Sulfadiazine Alone in Partial-Thickness Burns

Not yet recruiting·DDr Muhammad Naveed Shahzad·N/A·NCT07367087·30 enrolled

2 more indications

Efficacy1 trial

Efficacy Of Autologous Epidermal Cell Suspension And Silver Sulfadiazine Ointment In Burn

Completed·SSCARM Institute, Tabriz, Iran·Phase 2·NCT03162367·40 enrolled

CAR1 trial

Topical Collagen-Silver Versus Standard Care Following Removal of Ingrown Nails

Unknown status·RRosalind Franklin University of Medicine and Science·N/A·NCT00641433·80 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

SILVADENE

NDA NDA017381

Feb 25, 1982

SSD

NDA NDA018578

Dec 23, 1985

THERMAZENE

NDA NDA018810

Nov 30, 1989

SILDAFLO

NDA NDA019608

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Silver Sulfadiazine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Silver Sulfadiazine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Silver Sulfadiazine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA019608). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Rosalind Franklin University of Medicine and Science company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: RRosalind Franklin University of Medicine and Science

Silvadene

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Burns1 trial

Effectiveness1 trial

Burn1 trial

Breast Cancer1 trial

Hyaluronic Acid1 trial

Efficacy1 trial

CAR1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News